Athenagen's eye drop therapy for AMD is safe and well tolerated in Phase I study.

(From Chemical Business NewsBase - Press Release)

Athenagen Inc announced the completion of a Phase I clinical study of ATG3, the company's topical eye drop therapy for neovascular age-related macular degeneration (AMD). ATG3, a proprietary ophthalmic formulation of mecamylamine, is an antagonist of the nicotinic acetylcholine (nACh) receptor pathway that mediates angiogenesis. Studies in animal models have demonstrated excellent penetration of the proprietary ATG3 formulation to the retina and choroid following eye drop application. ATG3 was evaluated in a randomised, double-masked, placebo-controlled Phase I study which enrolled 80 healthy volunteers in single and …